BiotechTube
Home/Acelot/Katie Planey, PhD, MBA
KP

Katie Planey, PhD, MBA

Chief Executive Officer

Acelot

Therapeutic Areas

Neurodegenerative DiseasesAmyotrophic Lateral Sclerosis

Acelot Pipeline

DrugIndicationPhase
ACE-2223Amyotrophic Lateral Sclerosis (ALS)Preclinical

Leadership Team at Acelot

LW
Lewis Whitehead, PhD
Vice President of Research, Computational Discovery
MG
Marcie Glicksman, PhD
Acting Chief Scientific Officer
VT
Valarie Truax, PhD, MBA
Vice President, Business Development and Corporate Strategy
View full Acelot profile